Bronchial asthma as neurogenic paroxysmal inflammatory disease: A randomized trial with carbamazepine

Summary 

Purpose

Based on the assumption that bronchial asthma has not only inflammatory, but also certain neurogenic paroxysmal mechanism and pathophysiological links with other non-epileptic paroxysmal inflammatory diseases—migraine and trigeminal neuralgia, we decided to investigate efficacy of antiepileptic drug carbamazepine in patients with moderate persistent or severe asthma.

Methods

Sixty-three patients completed randomized double-blind, placebo-controlled trial.

Results

Stable remission was achieved after carbamazepine treatment in 25 patients in active group (). No significant improvement was registered in patients of placebo group (). Following open-label treatment shows high and stable antiasthmatic efficacy of carbamazepine monotherapy.

Conclusions

Carbamazepine showed high efficacy in therapy of moderate persistent or severe bronchial asthma. Antiasthmatic activity of carbamazepine can be considered as influence on neurogenic mechanisms of asthma. We suppose that it is possible to use carbamasepine for therapy of bronchial asthma in clinical practice.

Keywords: Asthma, Antiepileptic drugs, Efficacy, Carbamazepine, Placebo-controlled trial